Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Stacey Martiniano

Concepts (125)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cystic Fibrosis
37
2026
1164
7.320
Why?
Mycobacterium Infections, Nontuberculous
17
2025
339
4.660
Why?
Nontuberculous Mycobacteria
11
2023
189
3.130
Why?
Cystic Fibrosis Transmembrane Conductance Regulator
6
2026
373
1.310
Why?
Mycobacterium avium-intracellulare Infection
3
2021
63
1.160
Why?
Neonatal Screening
4
2023
185
0.950
Why?
Ethambutol
1
2021
27
0.670
Why?
Rifampin
1
2021
79
0.650
Why?
Rhodospirillaceae
1
2020
4
0.640
Why?
Mycobacterium abscessus
4
2025
110
0.640
Why?
Azithromycin
1
2021
101
0.630
Why?
Venous Thromboembolism
2
2021
330
0.590
Why?
Mycobacterium avium Complex
3
2021
87
0.580
Why?
Sputum
3
2020
302
0.560
Why?
Respiratory Tract Diseases
1
2020
178
0.560
Why?
Genetic Testing
1
2021
491
0.540
Why?
Clofazimine
1
2017
15
0.510
Why?
Algorithms
2
2021
1843
0.480
Why?
Aminophenols
4
2026
204
0.480
Why?
Meconium Ileus
2
2026
12
0.440
Why?
Coinfection
4
2020
143
0.430
Why?
Humans
39
2026
145625
0.380
Why?
Tuberculosis, Pulmonary
1
2014
127
0.370
Why?
Mutation
5
2023
4082
0.350
Why?
Quinolones
4
2026
204
0.350
Why?
Precision Medicine
1
2016
462
0.350
Why?
Pneumonia
1
2017
633
0.330
Why?
Microbial Sensitivity Tests
3
2021
367
0.310
Why?
Disease Management
1
2014
649
0.300
Why?
Lung Diseases
1
2016
787
0.300
Why?
Pyrazoles
2
2024
516
0.300
Why?
Indoles
2
2024
509
0.300
Why?
Pyridines
2
2024
606
0.290
Why?
Infant, Newborn
6
2024
6449
0.290
Why?
Retrospective Studies
9
2022
17291
0.280
Why?
Pseudomonas aeruginosa
3
2021
392
0.250
Why?
Morbidity
2
2019
317
0.240
Why?
Pyrrolidines
2
2024
126
0.220
Why?
Phage Therapy
1
2025
17
0.220
Why?
Child
8
2022
22638
0.210
Why?
Benzodioxoles
2
2024
164
0.210
Why?
Leprostatic Agents
1
2022
6
0.190
Why?
Fetal Diseases
1
2024
192
0.190
Why?
Delayed Diagnosis
1
2023
102
0.180
Why?
Infant
5
2023
10093
0.180
Why?
Aspergillosis, Allergic Bronchopulmonary
1
2021
11
0.170
Why?
Trypsinogen
1
2021
11
0.170
Why?
Adolescent
7
2021
22451
0.170
Why?
Quality Improvement
3
2020
1325
0.170
Why?
Antibiotics, Antitubercular
1
2021
35
0.170
Why?
Cohort Studies
4
2022
6045
0.170
Why?
Oropharynx
1
2021
46
0.160
Why?
Chloride Channel Agonists
2
2024
111
0.160
Why?
Symptom Flare Up
1
2020
37
0.160
Why?
Bacteriophages
1
2022
110
0.160
Why?
Drug Therapy, Combination
1
2022
1034
0.150
Why?
Data Interpretation, Statistical
1
2021
365
0.150
Why?
Specimen Handling
1
2021
178
0.150
Why?
Mycobacterium tuberculosis
1
2022
325
0.140
Why?
Antitubercular Agents
1
2021
211
0.140
Why?
Cross-Over Studies
1
2021
612
0.140
Why?
Diagnostic Tests, Routine
1
2019
108
0.140
Why?
Treatment Outcome
5
2025
11744
0.140
Why?
Respiratory Function Tests
1
2020
543
0.140
Why?
Infection Control
1
2019
174
0.130
Why?
Clinical Trials as Topic
2
2025
1062
0.130
Why?
Risk Factors
4
2019
10840
0.120
Why?
Cross Infection
1
2019
258
0.120
Why?
Lipopolysaccharides
1
2020
861
0.120
Why?
Sensitivity and Specificity
1
2021
1992
0.120
Why?
United States
5
2021
16041
0.120
Why?
Anti-Bacterial Agents
3
2022
1935
0.120
Why?
Anti-Infective Agents
1
2019
234
0.120
Why?
Radiography, Thoracic
1
2017
174
0.120
Why?
Anticoagulants
1
2021
743
0.110
Why?
Respiratory Tract Infections
1
2019
399
0.100
Why?
Genotyping Techniques
1
2014
72
0.100
Why?
Genetic Therapy
1
2016
303
0.100
Why?
Anti-Inflammatory Agents
1
2017
473
0.100
Why?
Genetic Markers
1
2014
337
0.100
Why?
Male
9
2025
73014
0.100
Why?
DNA Mutational Analysis
1
2014
409
0.090
Why?
Dose-Response Relationship, Drug
1
2017
2018
0.090
Why?
Mycobacterium Infections
1
2013
55
0.090
Why?
Female
9
2026
79080
0.090
Why?
Neutrophil Activation
1
2013
84
0.090
Why?
Prospective Studies
2
2025
8087
0.090
Why?
Case-Control Studies
1
2020
3633
0.090
Why?
Forced Expiratory Volume
1
2014
451
0.090
Why?
Young Adult
4
2020
14240
0.090
Why?
Global Health
1
2015
402
0.090
Why?
Registries
1
2021
2382
0.090
Why?
Decision Making
1
2019
987
0.090
Why?
Mycobacterium
1
2013
101
0.090
Why?
Pseudomonas Infections
1
2014
229
0.090
Why?
Prevalence
1
2019
2852
0.090
Why?
Child, Preschool
3
2021
11888
0.080
Why?
Genotype
1
2016
1866
0.080
Why?
Adult
6
2025
40821
0.080
Why?
Metagenomics
2
2021
153
0.080
Why?
Disease Progression
1
2016
2857
0.070
Why?
Follow-Up Studies
1
2017
5397
0.060
Why?
Diabetes Mellitus, Type 2
1
2021
2623
0.060
Why?
Genomics
2
2021
851
0.060
Why?
Animals
2
2019
38030
0.060
Why?
Aged, 80 and over
1
2017
8351
0.050
Why?
Lung
3
2022
4119
0.050
Why?
Quinolines
1
2024
191
0.050
Why?
Drug Combinations
1
2024
399
0.050
Why?
Multicenter Studies as Topic
1
2025
413
0.050
Why?
Mycobacterium avium
1
2023
21
0.050
Why?
Pregnancy
2
2026
7217
0.040
Why?
Aspergillus fumigatus
1
2021
26
0.040
Why?
Immunoglobulin M
1
2023
284
0.040
Why?
Complement System Proteins
1
2023
324
0.040
Why?
Middle Aged
2
2020
36359
0.030
Why?
Neutrophils
1
2023
1132
0.030
Why?
Aged
1
2017
26251
0.030
Why?
Predictive Value of Tests
1
2020
2097
0.030
Why?
Pilot Projects
1
2020
1878
0.030
Why?
Superoxides
1
2013
198
0.020
Why?
Incidence
1
2017
2910
0.020
Why?
Biofilms
1
2013
288
0.020
Why?
Biomarkers
1
2020
4329
0.020
Why?
Gene Expression Profiling
1
2013
1790
0.010
Why?
Martiniano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)